Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of 0.18% versus 0.3% sodium hyaluronate in ocular surface disease after trabeculectomy with mitomycin-C
TCTR20220524003Phase 4Unknown
- Sponsor
- Faculty of Medicine
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of sodium hyaluronate in ocular surface disease (OSD), Glaucoma, sponsored by Faculty of Medicine. Status: unknown.
02
Drugs
sodium hyaluronate
03
Conditions
ocular surface disease (OSD)Glaucoma
Beyond the preview
Go deeper on TCTR20220524003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220524003.